AtriCure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2018 and Full Year of 2019
January 07, 2019 at 07:00 pm IST
Share
AtriCure, Inc. provided revenue guidance for the fourth quarter and full year of 2018 and full year of 2019. Preliminary, unaudited revenue for fourth quarter 2018 is expected to be approximately $52.9 million, reflecting growth of approximately 15% over the fourth quarter of 2017.
Preliminary revenue for full year 2018 is expected to be $201.6 million, reflecting growth of approximately 15% over full year 2017.
Management projects 2019 revenue of approximately $220 million to $228 million, reflecting growth of approximately 9% to 13% over full year 2018.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE, INC. 
